Pharma & Biotech Mergers & Acquisitions News
Biotechnology
Gene therapy company Genprex (Nasdaq: GNPX) has announced plans to transfer its diabetes program and related assets into a new, wholly-owned subsidiary. 5 September 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Biotechnology
Gene therapy company Genprex (Nasdaq: GNPX) has announced plans to transfer its diabetes program and related assets into a new, wholly-owned subsidiary. 5 September 2024
Pharmaceutical
Semnur Pharmaceuticals and Denali Capital Acquisition and special purpose acquisition company (Nasdaq: DECA, the “SPAC”), have signed an agreement and plan of merger for a proposed business combination. 4 September 2024
Pharmaceutical
Plenty of money changed hands in pharmaceutical M&A terms in August, albeit big pharma companies were largely not involved. 3 September 2024
Pharmaceutical
Last week’s research news featured a new study from Eli Lilly, showing tirzepatide – the active ingredient of its diabetes drug Mounjaro and obesity treatment Zepbound – can delay the onset of diabetes. On the financial reporting front, Denmark’s Lundbeck released strong first-half results and raised its full year guidance. A new company – Borealis Biosciences – emerged from stealth last week, with funding from Novartis and Versant Ventures. Also of note, US biotech major Regeneron had a setback, when the Food and Drug Administration (FDA) issued a complete response letter (CRL) regarding the biologics license application (BLA) for its multiple myeloma candidate linvoseltamab. 25 August 2024
Pharmaceutical
Rafael Holdings (NYSE: RFL) and Cyclo Therapeutics (Nasdaq: CYTH) have agreed to merge, with the goal of focusing on the development of Trappsol Cyclo (hydroxypropyl beta cyclodextrin). 23 August 2024
Biotechnology
Next-gen RNA-focused biotech Borealis Biosciences has emerged from stealth with $150 million in combined Series A financing from founding investor Versant Ventures and Swiss pharma giant Novartis. 23 August 2024
Biotechnology
BridgeBio Pharma (Nasdaq: BBIO) has announced the formation of a new joint venture, GondolaBio, in collaboration with a syndicate of prominent investors. 22 August 2024
Pharmaceutical
Visiox Pharmaceuticals, a biopharma company based in Ohio, USA, has entered into a definitive merger agreement with Ocuvex Therapeutics. 20 August 2024
Pharmaceutical
Crown Laboratories, a privately held skincare company, and Nashville, USA-based Revance Therapeutics have entered into an agreement whereby the companies seek to merge the two complementary organizations. 13 August 2024
Biotechnology
Last week’s news included second quarter financial results from BioNTech, the German mRNA biotech behind the successful covid vaccine Comirnaty, along with an update on its R&D pipeline. On the deal-making front, US biotech Equillium announced progress for its graft-versus-host disease drug itolizumab that is partnered with Japan’s Ono Pharmaceutical. Also, US gene editing firm Sangamo signed a licensing deal with Roche subsidiary Genentech that could earn it more than $2 billion. M&A news saw US firm Recursion enter a merger agreement with the UK’s Exscientia. Eli Lilly reported second quarter financial that beat expectations, driven by the performances of its new diabetes and obesity drugs. 11 August 2024
Biotechnology
US AI-enabled biotech Recursion and UK-based Exscientia today announced the companies have entered into a definitive merger agreement. 8 August 2024
Pharmaceutical
Denmark US oncology-based Pharmacosmos today revealed it has entered a definitive agreement to acquire US cancer-focused company G1 Therapeutics. 7 August 2024
Pharmaceutical
A quiet June gave way to a busier July in pharma M&A markets. 2 August 2024
Biotechnology
Japanese drugmaker Otsuka Pharmaceuticals is to buy privately-held US biotech Jnana Therapeutics. 1 August 2024
Pharmaceutical
Major pharmaceutical multinationals are looking to collaborate with Indian drug firms, leveraging their cost-efficient manufacturing capabilities, robust supply chains, and innovative research potential. 31 July 2024
Biotechnology
Tigermed (SZ: 300347), a global clinical research solution provider, has completed a move to boost capabilities in Japan and beyond, with the acquisition of the contract research organization (CRO) Medical Edge. 31 July 2024
Biotechnology
Boehringer Ingelheim today said it is taking a significant step in expanding its oncology pipeline of cancer cell-directed and immuno-oncology offering. 30 July 2024
Pharmaceutical
India’s Mankind Pharma has entered into a definitive agreement to acquire a 100% stake in Bharat Serums and Vaccines (BSV) from Advent International. 26 July 2024
Pharmaceutical
US companies Palvella Therapeutics and Pieris Pharmaceuticals have agreed to merge in an all-stock transaction. 24 July 2024
Biotechnology
British life science incubator Syncona has launched a new gene therapy company, Beacon Therapeutics, in the ophthalmology space. 4 April 2024
Biotechnology
Having already signed up licensing deals in the ever-growing interest in the antibody-conjugates (ADCs) arena, Danish biotech Genmab is now going further with an outright company acquisition. 3 April 2024
Pharmaceutical
Deal flow was heavy in pharmaceutical M&A during March. 2 April 2024
Biotechnology
US biopharma Onconova Therapeutics is to buy Trawsfynydd Therapeutics. 2 April 2024
Pharmaceutical
The pharma company known as Sosei Group or Sosei Heptares will now go by the name Nxera Pharma. 2 April 2024
Biotechnology
M&A news continued last week, with US pharma major AbbVie announcing it was buying Landos Biopharma and its inflammatory diseases candidate NX-13, for up to $212,5 million. On the regulatory front, UK pharm major AstraZeneca scored a US Food and Drug Administration (FDA) approval for a new indication for Ultomiris. Merck & Co won an important FDA approval for its pulmonary arterial hypertension (PAH) candidate Winrevair (sotatercept). 89bio received PRIME designation from the European Medicines Agency (EMA) for its liver disease candidate pegozafermin. Also, Applied Therapeutics announced that the FDA had requested additional time to review the rare disease drug developer’s application for govorestat for the treatment of classic galactosemia. 31 March 2024
Pharmaceutical
Veeda Clinical Research Limited, a full-service contract research organization (CRO) with a proven record of drug development success, announced that it has acquired Heads, a privately held European CRO, which specializes in conducting clinical trials in oncology. 27 March 2024
Pharmaceutical
Cohance Lifesciences and Suven Pharma are to merge, creating one of India's largest integrated contract development and manufacturing organization (CDMO) players. 26 March 2024
Pharmaceutical
New York-based Nuvation Bio, a biopharma tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, is to buy AnHeart Therapeutics. 26 March 2024
Biotechnology
US pharma major AbbVie is to acquire Landos Biopharma, news that sent the latter company’s share price rocketing by 165% during Monday morning’s trading. 25 March 2024
Generics
KELIX bio, an emerging markets biopharmaceuticals platform, has been sold to Mubadala Investment Company, an Abu Dhabi investor with over $276 billion in assets under management. 25 March 2024
Biotechnology
Danish diabetes and obesity giant Novo Nordisk is continuing its deal-making and M&A activity, today revealing plans to add to its cardiovascular portfolio. 25 March 2024
Biotechnology
On the M&A front last week, UK pharma major AstraZeneca announced an agreement to acquire Canadian radiopharma company Fusion Pharmaceuticals for $2 billion upfront and a further $400 million contingent. Crinetics Pharmaceuticals released new Phase III data on its investigational drug paltusotine in acromegaly. Japanese drugmaker Kyowa Kirin’s subsidiary Orchard Therapeutics set out US launch plans for its newly Food and Drug Administration (FDA) approved rare disease cell therapy Lenmeldy with a list price of $4.25 million. Also of note, on the regulatory front, Japan’s largest drugmaker Takeda gained an expanded indication for its Iclusig for leukemia. 25 March 2024
Pharmaceutical
Shares of Canada-headquartered Fusion Pharmaceuticals were up more than 95% at $20.80 in pre-market activity, on the news of a takeover bid from UK pharma major AstraZeneca. 19 March 2024
Biotechnology
Among research news last week, Swiss clinical-stage biotech MoonLake Immunotherapies held an R&D day, when it presented new data on its pipeline, emphasizing the success of its sonelokimab in psoriatic arthritis. Also, US pharma giant Pfizer released Phase III data on its Adcetris for the treatment of B-cell lymphoma. On the regulatory front, the US Food and Drug Administration (FDA) last week approved Mirum Pharmaceuticals’ Livmarli for the new indication of intrahepatic cholestasis (PFIC). Also of note, US pharma major ELI Lilly linked up with Amazon Pharmacy to make its products, including the new obesity drug Zepbound, available to patients. And the UK’s AstraZeneca announced a takeover bid for USA-based Amolyt Pharma for up to $1.05 billion. 17 March 2024
Biotechnology
Having agreed three M&A deals last year, UK pharma major AstraZeneca today announced another. 14 March 2024
Biotechnology
Privately-held US biotech IFM Therapeutics today announced that Swiss pharma giant Novartis has exercised its option to acquire all of the outstanding capital stock of its subsidiary, IFM Due. 13 March 2024
Generics
Generic drugmaker Aspire Pharma today announced the successful completion of its acquisition of fellow UK-based Cenoté Pharma, in continuation of its strong organic growth. 11 March 2024
Biotechnology
Israeli company BiomX has entered into a definitive merger agreement with Adaptive Phage Therapeutics, a USA-based, privately-held, biotech developing phage-based therapies to combat bacterial infections. 6 March 2024
Pharmaceutical
Melbourne-based Telix has entered into an agreement to acquire the Canadian radioisotope production technology firm ARTMS. 6 March 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze